Lady Era is a prescription medication specifically formulated to address hypoactive sexual desire disorder (HSDD) in premenopausal women. Developed through rigorous clinical research, this pharmaceutical-grade treatment works by enhancing blood flow to the genital area and modulating neurotransmitter activity to support healthy sexual response. The medication represents a scientifically-validated approach to female sexual health that has demonstrated significant efficacy in controlled trials while maintaining an established safety profile under proper medical supervision.

Features

• Contains 100mg of sildenafil citrate as the active pharmaceutical ingredient
• Tablet formulation designed for oral administration with water
• Precisely calibrated dosage strength based on clinical trial data
• Manufactured in FDA-approved facilities following GMP standards
• Packaged in blister packs to maintain product integrity and stability
• Includes comprehensive patient information literature

Benefits

• Increases blood flow to genital tissues to support physiological arousal
• May enhance sensitivity and responsiveness to sexual stimulation
• Supports improved sexual satisfaction and intimacy
• Provides a pharmaceutical option for diagnosed sexual dysfunction
• Works within the body’s natural physiological processes
• Effects are temporary and dose-dependent

Common use

Lady Era is prescribed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This condition is characterized by persistently deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The medication is not indicated for sexual dysfunction related to coexisting medical or psychiatric conditions, relationship problems, or the effects of substance abuse. Clinical use requires proper diagnosis by a qualified healthcare provider who has ruled out other potential causes of decreased sexual desire.

Dosage and direction

The recommended dosage is one 100mg tablet taken approximately 30-60 minutes before anticipated sexual activity. The tablet should be swallowed whole with a full glass of water. Administration with a high-fat meal may delay the onset of action. The maximum recommended dosing frequency is once per day. Healthcare providers may initiate therapy at a lower dose (50mg) for patients who experience side effects or have specific medical considerations. Dosage adjustments should only be made under medical supervision.

Precautions

Patients should undergo thorough medical evaluation before beginning treatment. Cardiovascular status should be assessed, as sexual activity carries potential cardiac risk for individuals with preexisting heart conditions. Use caution in patients with anatomical deformation of the penis, conditions that might predispose to priapism, bleeding disorders, or active peptic ulceration. Ophthalmic examination is recommended for patients with retinitis pigmentosa or other retinal disorders. Hepatic impairment or severe renal impairment may require dosage adjustment.

Contraindications

Concomitant administration with organic nitrates in any form is absolutely contraindicated. Additional contraindications include hypersensitivity to sildenafil citrate or any component of the tablet, concurrent use with guanylate cyclase stimulators, and patients for whom sexual activity is inadvisable due to cardiovascular risk. The medication is not indicated for use by men, postmenopausal women, or women without a diagnosis of HSDD.

Possible side effects

Common adverse reactions include headache (15-28%), flushing (10-26%), dyspepsia (4-17%), nasal congestion (4-12%), and dizziness (2-9%). Visual disturbances including altered color perception, blurred vision, and photophobia have been reported in 3-11% of patients. Less frequently reported effects include rash, urinary tract infection, and transient hypotension. Serious side effects requiring immediate medical attention include priapism, sudden hearing loss, vision loss, and cardiovascular events.

Drug interaction

Concomitant use with nitrates may cause potentially fatal hypotension. Alpha-blockers may enhance the hypotensive effects. CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) may increase sildenafil concentrations. CYP3A4 inducers (rifampin, phenobarbital) may decrease efficacy. Grapefruit juice may increase bioavailability. Use with other erectogenic agents is not recommended. Caution is advised when coadministered with antihypertensive medications.

Missed dose

As Lady Era is taken on an as-needed basis rather than a scheduled regimen, the concept of a “missed dose” does not apply in the conventional sense. Patients should simply take the medication when needed for sexual activity, maintaining at least a 24-hour interval between doses. Do not double the dose to make up for a missed administration.

Overdose

In cases of suspected overdose, seek immediate medical attention. Symptoms may include severe headache, visual disturbances, nausea, vomiting, dizziness, syncope, and hypotension. Standard supportive measures should be employed, including maintaining blood pressure and adequate hydration. Hemodialysis does not significantly accelerate clearance due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature (15-30°C or 59-86°F) in the original packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any tablets that show signs of physical damage or deterioration.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Lady Era is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Individual results may vary. Patients should disclose their complete medical history and current medications to their prescribing physician. This product is not intended to diagnose, treat, cure, or prevent any disease.

Reviews

Clinical studies involving over 3,000 women demonstrated that 60-70% of participants reported improvement in sexual desire and satisfaction compared to 30-35% in placebo groups. Patient-reported outcomes indicated significant improvement in distress related to sexual desire. The majority of adverse events were mild to moderate in severity and transient in nature. Long-term follow-up studies (up to 2 years) have shown maintained efficacy with continuous use under medical supervision.